284,783 Shares in United Therapeutics Corporation $UTHR Acquired by Caisse de depot et placement du Quebec

Caisse de depot et placement du Quebec purchased a new stake in United Therapeutics Corporation (NASDAQ:UTHR) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 284,783 shares of the biotechnology company’s stock, valued at approximately $154,304,000.

Several other hedge funds also recently added to or reduced their stakes in the stock. Gallagher Fiduciary Advisors LLC acquired a new stake in United Therapeutics during the second quarter worth approximately $307,000. Odyssean LLC boosted its holdings in shares of United Therapeutics by 76.4% in the 2nd quarter. Odyssean LLC now owns 5,445 shares of the biotechnology company’s stock valued at $2,950,000 after buying an additional 2,358 shares in the last quarter. Man Group plc acquired a new position in shares of United Therapeutics in the 2nd quarter valued at $73,087,000. Roberts Glore & Co. Inc. IL purchased a new position in shares of United Therapeutics in the 2nd quarter valued at $244,000. Finally, Jupiter Topco LLC purchased a new position in shares of United Therapeutics in the 2nd quarter valued at $450,140,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $511.97, for a total value of $4,863,715.00. Following the transaction, the chief executive officer owned 324,443 shares in the company, valued at $166,105,082.71. The trade was a 2.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Paul A. Mahon sold 8,300 shares of the company’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $523.14, for a total value of $4,342,062.00. Following the sale, the executive vice president directly owned 45,172 shares of the company’s stock, valued at approximately $23,631,280.08. This represents a 15.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 424,075 shares of company stock valued at $227,683,710 in the last quarter. Insiders own 8.60% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Bank of America cut their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Weiss Ratings raised United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, August 13th. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Royal Bank Of Canada cut their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a research report on Thursday, August 6th. Finally, JPMorgan Chase & Co. boosted their target price on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $646.00.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $516.68 on Thursday. The stock has a market cap of $22.16 billion, a P/E ratio of 18.49, a P/E/G ratio of 1.76 and a beta of 0.59. The firm has a fifty day moving average price of $531.06 and a 200 day moving average price of $538.56. United Therapeutics Corporation has a 1-year low of $302.19 and a 1-year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.86 by $0.41. The company had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. United Therapeutics’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same period last year, the firm posted $6.41 EPS. Sell-side analysts expect that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.